Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Capmatinib inhibits MET phosphorylation by hepatocyte growth factor binding or triggered by MET amplification, as well as MET-mediated phosphorylation of downstream signaling prote···【more】
Article source：Captain MedicineRelease date：2024-08-06Recommended：264
Fidaxomicin is prescribed for the management of Clostridium difficile associated diarrhea in individuals aged 6 months and beyond. It is imperative for patients to remain vigilant ···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：305
Fidaxomicin received its initial approval from the Food and Drug Administration (FDA) in the United States in 2011 and has since been effectively commercialized. This article serve···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：321
Fidaxomicin, a potent macrolide antibiotic renowned for its ability to impede bacterial growth and reproduction by disrupting metabolic pathways within bacterial cells, holds promi···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：338
Clostridium difficile, a prevalent enteric pathogen, is known to induce profound diarrhea and occasionally necessitate hospitalization. Fidaxomicin, a therapeutic agent, aids in th···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：297
Fidaxomicin, a macrolide antibiotic sanctioned by the US FDA in 2011, boasts a distinctive mechanism of action. This medication predominantly hinders the RNA polymerase of bacteria···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：330
Fidaxomicin, a potent macrolide antibiotic, is primarily utilized in the treatment of infections attributed to specific bacterial strains, serving as a pivotal therapeutic agent ag···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：295
Fidaxomicin is a pharmaceutical agent specifically indicated for the treatment of diarrhea associated with Clostridium difficile. The assessment of the gravity of adverse events st···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：270
Fidaxomicin, a potent antibiotic medication, serves as a pivotal remedy for the treatment of diarrheal conditions stemming from a Clostridium difficile infection, showcasing signif···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：296
Anamorelin represents a pioneering intervention for cancer-associated cachexia, devised to mitigate the deterioration of nutritional status and weight loss prevalent in individuals···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：346
Through its distinctive mechanism of action, Anamorelin presents novel therapeutic modalities for individuals afflicted by cachexia, thereby enhancing their nutritional state and e···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：284
Fidaxomicin is indicated for the treatment of difficult Clostridioides difficile-associated diarrhea in adults and children aged 6 months and above. Fidaxomicin hastwo main differe···【more】
Article source：Captain MedicineRelease date：2024-08-05Recommended：367
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：4412025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：6242024-09-07
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended：832026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：4072025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：4242025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：4112025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：4672025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3792025-01-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
